Erratum to: JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

Affiliations

¹ Rheumatology Fellowship and Training Branch, National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, USA. shubhasree.banerjee@nih.gov.
² Clinical Center, National Institutes of Health, Bethesda, USA.
³ Translational Immunology Section, National Institute of Arthritis Musculoskeletal and Skin diseases, National Institutes of Health, Bethesda, USA.
⁴ Lupus Clinical Research Program, National Institute of Arthritis Musculoskeletal and Skin diseases, National Institutes of Health, Bethesda, USA.
⁵ Molecular Immunology and Inflammation Branch, National Institute of Arthritis Musculoskeletal and Skin diseases, National Institutes of Health, Bethesda, USA.

Published Erratum

Shubhasree Banerjee et al. Drugs. 2017 Jul.

. 2017 Jul;77(11):1261.

doi: 10.1007/s40265-017-0772-7.

¹ Rheumatology Fellowship and Training Branch, National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, USA. shubhasree.banerjee@nih.gov.
² Clinical Center, National Institutes of Health, Bethesda, USA.
³ Translational Immunology Section, National Institute of Arthritis Musculoskeletal and Skin diseases, National Institutes of Health, Bethesda, USA.
⁴ Lupus Clinical Research Program, National Institute of Arthritis Musculoskeletal and Skin diseases, National Institutes of Health, Bethesda, USA.
⁵ Molecular Immunology and Inflammation Branch, National Institute of Arthritis Musculoskeletal and Skin diseases, National Institutes of Health, Bethesda, USA.

No abstract available

Erratum for

JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. Banerjee S, et al. Drugs. 2017 Apr;77(5):521-546. doi: 10.1007/s40265-017-0701-9. Drugs. 2017. PMID: 28255960 Free PMC article. Review.